10-Q: Verano Holdings Corp. Q1 2026 Earnings Decline Amidst Competition

Verano Holdings Corp. reported a slight revenue decrease and an increased net loss for Q1 2026, primarily due to increased competition in wholesale markets and a significant debt extinguishment charge.

Summary

• Verano Holdings Corp. reported revenues of $208.18 million for the first quarter of 2026, a decrease of 0.8% compared to $209.81 million in the same period of 2025.
• Gross profit was $98.98 million, with a gross profit margin of 47.5%, consistent with the prior year.
• The company reported a net loss attributable to Verano Holdings Corp. of $17.82 million for Q1 2026, an increase from a net loss of $11.52 million in Q1 2025.
• This widened net loss was significantly impacted by a $5.74 million loss on debt extinguishment related to the 2022 Credit Agreement.
• Selling, General, and Administrative (SG&A) expenses increased by 1.5% to $85.88 million, representing 41.3% of revenue, up from 40.3% in the prior year.
• Cash and cash equivalents decreased to $74.03 million as of March 31, 2026, from $82.72 million as of December 31, 2025.
• The company opened two new stores in Florida during the quarter.
• A significant development is the federal rescheduling of medical cannabis to Schedule III, which, if finalized with IRS guidance, could alleviate Section 280E tax implications for medical operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, decreased revenues, and rising operational costs, despite some positive retail performance and the potential future benefit from cannabis rescheduling.

Positives

• Retail revenues increased by 2.0% to $172.14 million, driven by new product launches and operational efficiencies.
• The company opened two new retail dispensaries in Florida.
• The gross profit margin remained stable at 47.5%.
• Net cash provided by operating activities significantly improved to $18.59 million from $1.79 million in the prior year.
• The company's working capital increased by $11.22 million to $275.61 million.
• The federal rescheduling of medical cannabis to Schedule III, announced on April 23, 2026, offers potential relief from Section 280E tax constraints for medical operations.

Negatives

• Total revenues decreased by 0.8% to $208.18 million.
• Net loss attributable to Verano Holdings Corp. increased by $6.31 million to $17.82 million.
• Wholesale (cultivation) revenues decreased by 0.9% due to increased competition and promotional activity.
• SG&A expenses increased by 1.5% and as a percentage of revenue, indicating rising operational costs.
• A significant loss on debt extinguishment of $5.74 million impacted the net loss.
• Cash and cash equivalents decreased by $8.69 million during the quarter.

Risks

• Continued increased competition and promotional activity in third-party wholesale markets.
• The federal rescheduling of cannabis to Schedule III is not guaranteed to be finalized in a way that benefits the company, and adult-use cannabis remains Schedule I.
• Potential for price compression at the cultivation (wholesale) level as state markets mature.
• Reliance on key management personnel.
• The immaturity of the cannabis industry and limited comparable industry best practices.
• The ongoing complexity of navigating disparate state-by-state regulatory landscapes and licensing regimes.
• The potential for fraudulent activity by employees, contractors, and consultants.
• The risk of civil asset forfeiture.
• The impact of Section 280E of the Internal Revenue Code on U.S. cannabis companies, although potential relief is on the horizon for medical cannabis.

Future Outlook

The company expects to meet its short-term liquidity requirements through internally generated funds and available cash balances. Long-term liquidity needs are expected to be met through operating cash flow, debt or equity issuances, and other borrowings. The company anticipates that the federal rescheduling of medical cannabis to Schedule III could alleviate Section 280E tax constraints for its medical operations, though formal IRS guidance is pending.

Management Comments

• The increase in net loss was largely driven by a loss on debt extinguishment related to the 2022 Credit Agreement for the three months ended March 31, 2026 when compared to the three months ended March 31, 2025.
• The increase in retail revenues, net of discounts, was primarily driven by successful new product launches and operational efficiencies when comparing the three months ended March 31, 2026 to the three months ended March 31, 2025.
• In the core markets in which the Company is already operational and, as the state markets mature, the Company has experienced pressure on margins within the cultivation (wholesale) and retail segments and expects this to continue.
• The Company has taken a position that it does not owe taxes attributable to the application of Section 280E of the Code.

Industry Context

StockSavvy.ai notes that Verano's Q1 2026 results reflect the ongoing competitive pressures within the U.S. cannabis market, particularly in wholesale. The company's retail segment shows resilience with growth driven by new product introductions, a common strategy to combat market saturation. The potential impact of the federal rescheduling of medical cannabis to Schedule III is a significant development that could reshape the industry's tax landscape, a key concern for all U.S. cannabis operators.

Comparison to Industry Standards

• Verano's gross profit margin of 47.5% is within the typical range for vertically integrated cannabis operators, though margins can vary significantly by state and market maturity.
• The increase in SG&A as a percentage of revenue (41.3% vs. 40.3%) suggests that operational scaling and expansion costs are outpacing revenue growth in certain areas, a common challenge for MSOs expanding their footprint.
• The net loss, exacerbated by debt extinguishment costs, highlights the capital-intensive nature of the cannabis industry and the financial risks associated with debt financing, especially given the federal illegality which limits traditional banking relationships.

Legal Proceedings

• As of March 31, 2026, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations.

Related Party Transactions

• George Archos, CEO, funded $10,000 of the 2026 Credit Agreement through an affiliated entity.
• George Archos holds an indirect 50% ownership interest in 740 Rte. 59, LLC, from which Verano leases a retail dispensary property.
• George Archos holds a 50% indirect ownership interest in 783 Butterfield LLC, from which Verano leases a retail dispensary property.
• GP Management Group, LLC, controlled by George Archos, held a less than 1% ownership interest in Sweed, a point of sale software provider to Verano.
• John Tipton retired from his operational role and entered into a consulting agreement, receiving 909,090 RSUs and a monthly payment.

Stakeholder Impact

• Shareholders: Increased net loss and slight revenue decline may negatively impact share price. The share repurchase program could provide some support.
• Employees: Continued growth in retail and potential operational efficiencies may support employment. John Tipton's consulting role indicates continued engagement with key personnel.
• Creditors: The company repaid its 2022 Credit Agreement and secured new financing, indicating active management of its debt obligations. Compliance with covenants in the new 2026 Credit Agreement is noted.
• Suppliers: Continued operations in cultivation and retail imply ongoing relationships with suppliers.

Next Steps

• Continue to monitor the impact of the federal rescheduling of medical cannabis and await formal IRS guidance.
• Focus on operational efficiencies and new product launches to drive retail growth.
• Manage competitive pressures in the wholesale market.
• The company authorized a share repurchase program of up to 5% of outstanding common stock over 12 months, up to $20,000.
• A new hearing on the proposed rule for rescheduling all forms of cannabis is scheduled for June 29, 2026.

Key Dates

Recommendation

Verano Holdings Corp. presents a mixed financial picture. While retail segment growth and the potential positive impact of cannabis rescheduling are encouraging, the overall revenue decline, increased net loss, and ongoing competitive pressures in the wholesale market warrant a cautious approach. The company's ability to navigate these challenges and capitalize on regulatory changes will be key. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the full impact of rescheduling and sustained improvement in operational performance.

Keywords

Verano Holdings Corp., Cannabis, Multi-state operator, Q1 2026, Form 10-Q, Financial Results, Revenue, Net Loss, Debt Extinguishment, Section 280E, Schedule III Rescheduling, Retail, Wholesale, Nevada, Illinois, Florida